Concerning DKD, it is worth mentioning that the results of the study performed by Isakova et al., who analyzed the impact of baseline FGF23 measured early in the course of a disease, that is, when eGFR equaled 90.9 ± 22.7 mL/min/1.73 m2 on the incidence of CKD (defined as permanent reduction of eGFR to less than 60 mL/min/1.73 m2) in a subset of patients included in the ACCORD trial (Action to Control CV Risk in Diabetes). The gene discussed is FGF23; the disease is diabetic kidney disease.